TD Cowen Boosts Travere Therapeutics (NASDAQ:TVTX) Price Target to $60.00

Key Points

• TD Cowen raised its price target on Travere Therapeutics to $60 (from $45) and maintained a "buy" rating, implying about a 35.9% upside, while multiple other brokers have also lifted targets and the consensus is a "Moderate Buy" with an average target around $46.58.
• TVTX traded at $44.15 with a market cap of about $4.08 billion and a negative trailing P/E, and the stock has a 12‑month range of $13.88 to $48.61, indicating recent recovery but continued volatility.
• Insiders have sold shares (317,370 shares worth ~$12.1M in the last 90 days, including pre‑arranged 10b5‑1 sales), even as the company highlights positive commercial and pipeline catalysts such as the FILSPARI approval, strong demand in IgAN, and the Phase 3 restart for pegtibatinase supporting longer‑term revenue growth.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) had its price target lifted by research analysts at TD Cowen from $45.00 to $60.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. TD Cowen's price target suggests a potential upside of 35.92% from the company's current price.

Several other research analysts have also recently issued reports on TVTX. HC Wainwright increased their price objective on shares of Travere Therapeutics from $47.00 to $57.00 and gave the company a "buy" rating in a report on Tuesday. Canaccord Genuity Group raised their price objective on shares of Travere Therapeutics from $47.00 to $56.00 and gave the stock a "buy" rating in a research note on Tuesday, April 14th. JPMorgan Chase & Co. decreased their target price on shares of Travere Therapeutics from $44.00 to $41.00 and set an "overweight" rating for the company in a research note on Wednesday, March 25th. Piper Sandler raised shares of Travere Therapeutics from a "neutral" rating to an "overweight" rating and set a $49.00 target price for the company in a research note on Tuesday, April 14th. Finally, Wedbush lifted their target price on shares of Travere Therapeutics from $53.00 to $55.00 and gave the stock an "outperform" rating in a report on Tuesday. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $46.58.

Travere Therapeutics Stock Performance

TVTX traded down $0.77 on Tuesday, hitting $44.15. 2,219,472 shares of the company's stock were exchanged, compared to its average volume of 2,151,058. The firm has a market cap of $4.08 billion, a PE ratio of -147.15 and a beta of 1.13. Travere Therapeutics has a twelve month low of $13.88 and a twelve month high of $48.61. The stock has a fifty day moving average of $32.02 and a two-hundred day moving average of $32.59. The company has a current ratio of 2.74, a quick ratio of 2.70 and a debt-to-equity ratio of 2.71.

Insider Buying and Selling

In other news, insider Elizabeth E. Reed sold 6,785 shares of the company's stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $41.83, for a total value of $283,816.55. Following the sale, the insider directly owned 105,211 shares in the company, valued at approximately $4,400,976.13. This represents a 6.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Roy D. Baynes sold 9,750 shares of the company's stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $44.22, for a total value of $431,145.00. Following the completion of the sale, the director owned 37,500 shares in the company, valued at approximately $1,658,250. This represents a 20.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 317,370 shares of company stock worth $12,100,486. Insiders own 4.44% of the company's stock.

Hedge Funds Weigh In On Travere Therapeutics

A number of large investors have recently modified their holdings of TVTX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Travere Therapeutics by 13.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,777 shares of the company's stock worth $1,029,000 after purchasing an additional 6,831 shares in the last quarter. Norges Bank acquired a new position in shares of Travere Therapeutics during the second quarter worth approximately $1,051,000. First Trust Advisors LP acquired a new position in shares of Travere Therapeutics during the second quarter worth approximately $3,538,000. Cresset Asset Management LLC lifted its position in shares of Travere Therapeutics by 26.5% during the second quarter. Cresset Asset Management LLC now owns 28,875 shares of the company's stock worth $427,000 after purchasing an additional 6,047 shares in the last quarter. Finally, Qube Research & Technologies Ltd lifted its position in shares of Travere Therapeutics by 106.2% during the second quarter. Qube Research & Technologies Ltd now owns 604,128 shares of the company's stock worth $8,941,000 after purchasing an additional 311,137 shares in the last quarter.

Travere Therapeutics News Roundup

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Company update: Travere highlighted a landmark approval of FILSPARI in FSGS, strong demand (including continued momentum in IgAN), and the restart/first new patient dosed in the Phase 3 HARMONY study for pegtibatinase — positive commercial and pipeline catalysts that support longer-term revenue growth. Travere Therapeutics Reports First Quarter 2026 Financial Results
• Positive Sentiment: Analyst support: several firms have raised targets or maintain buy/outperform views recently, providing third‑party validation for the commercial outlook and helping underpin the stock despite short-term noise. MarketBeat TVTX coverage
• Neutral Sentiment: Earnings call details: management commentary and the full Q1 transcript are available for investors to evaluate guidance, channel trends, and commercial execution described on the call. Review for nuance on demand trends and margin cadence. Travere Therapeutics, Inc. (TVTX) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Mixed quarter metrics: coverage notes the quarter showed strong year‑over‑year revenue growth but divergence vs. consensus on key line items — read the “compared to estimates” pieces for detail on which metrics beat or missed. Compared to Estimates, Travere (TVTX) Q1 Earnings
• Negative Sentiment: Revenue miss / mixed headline results: some outlets report the quarter missed revenue estimates and show variability in EPS comparisons across data providers — that topline shortfall is a near‑term catalyst for selling pressure. Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
• Negative Sentiment: Insider selling: Director Roy Baynes sold 9,750 shares under a pre‑arranged Rule 10b5‑1 plan; while planned sales reduce alarm compared with opportunistic selling, the disclosure can still weigh on sentiment. Insider Selling: Travere Therapeutics NASDAQ: TVTX Director Sells 9,750 Shares of Stock

About Travere Therapeutics

Travere Therapeutics, Inc NASDAQ: TVTX is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.